{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/33811"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/33811","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"Evaluation of Prostate Cancer-Associated Factors (SIG27, LINC01089, and FAM84B) and Their Contribution to Prostate Cancer Progression","abstract":"ABSTRACT Despite advances in understanding prostate cancer (PC) pathogenesis and the rapid development of new therapeutic approaches, PC remains the second leading cause of cancer death in men, highlighting the need to deepen our understanding of its etiology and improve patient management. Following curative-aimed therapies (surgery and chemotherapy), relapsed tumors (biochemical recurrence - BCR) develop with a significantly increased risk of metastasis. Given the fundamental role of androgen receptor (AR) in driving PC progression, metastatic PCs are standardly treated with androgen deprivation therapy (ADT). However, resistance frequently occurs in the form of castration-resistant PC (CRPC), representing the dominant cause of PC mortality. Metastatic PCs exhibit the highest level of chromosomal instability (CIN) among other metastatic cancers, and this genomic instability contributes to CRPC development. Collectively, improvements in PC management require advances in biomarkers for PC diagnosis and recurrence risk assessment, as well as a deeper understanding of PC-associated genomic instability. In this thesis, three complementary projects are presented that collectively advance our knowledge in prognostic stratification and molecular risk factors for PC progression. First, we evaluated the Sig27 multigene panel, previously developed in our lab as a potential predictor of PC relapse (Biochemical Recurrence - BCR). We demonstrate that Sig27 possesses predictive power for BCR comparable to Oncotype DX and is strongly associated with immune-related pathways in PC. Sig27 metagene expression is enriched in tumor-associated macrophages (TAMs) and positively correlates with multiple immune checkpoints (ICs), including HAVCR2, TIGIT and CD96. Analyzing their 27 component genes, we identified five genes (TFEC, FPR3, NOD2, LAMP3, and MCTP1) that primarily contribute to Sig27's association with immune-suppressive features of PC. Second, we further explored the role of a Sig27 gene component, LINC01089, in PC tumorigenesis, as a long non-coding RNA (lncRNA) previously implicated in other cancer types. Our findings reveal an oncogenic role for LINC01089: it enhances tumor cell proliferation and migration in vitro, promotes tumor growth in vivo, and confers resistance to androgen withdrawal in LNCaP and TRAMP-C2 cells. We further demonstrated that LINC01089 is upregulated in PC tumors and significantly predicts recurrence risk. In primary PCs, genes associated with LINC01089 are predominantly enriched in RNA splicing processes. Moreover, we constructed two novel multigene panels from the LINC01089 gene network, Overlap3 and Sig15, both of which captured RNA splicing features of PC and significantly predict recurrence. Given that RNA splicing is a common property of cancer, Sig15 also effectively stratifies poor prognosis across nine additional cancer types. Furthermore, we detected elevated circulating LINC01089 levels in plasma from 235 PC patients compared with 24 healthy individuals, benchmarking our data to PCA3, indicating a diagnostic potential of LINC01089 as a liquid-based biomarker. Third, we examined the possible association of FAM84B, previously characterized as a risk factor for PC in our lab, with the DNA damage response (DDR). Taking advantage of PC stable lines previously generated - FAM84B, FAM84B-ΔHRASLS (FAM84B mutant with a deletion of the HRASLS domain) and EV (empty vector) - we studied the impact of FAM84B on the DDR following etoposide-induced DNA damage. Our evidence indicates that FAM84B modulates DDR, as observed by reduced activation and/or recruitment of DDR factors including NSB1, ATM, H2AX, and CHEK2. Moreover, FAM84B conferred a survival advantage to tumor cells under DNA-damaging conditions. Altogether, these findings suggest that FAM84B mediated dysregulation of DDR may impair DNA repair, promote genome instability, and enhance tumorigenic potential. In conclusion, these studies integrate biomarker exploration with functional studies to uncover novel determinants of PC progression, providing insights with potential relevance for improving PC risk assessment and therapeutic strategies.","abstract_html":"ABSTRACT Despite advances in understanding prostate cancer (PC) pathogenesis and the rapid development of new therapeutic approaches, PC remains the second leading cause of cancer death in men, highlighting the need to deepen our understanding of its etiology and improve patient management. Following curative-aimed therapies (surgery and chemotherapy), relapsed tumors (biochemical recurrence - BCR) develop with a significantly increased risk of metastasis. Given the fundamental role of androgen receptor (AR) in driving PC progression, metastatic PCs are standardly treated with androgen deprivation therapy (ADT). However, resistance frequently occurs in the form of castration-resistant PC (CRPC), representing the dominant cause of PC mortality. Metastatic PCs exhibit the highest level of chromosomal instability (CIN) among other metastatic cancers, and this genomic instability contributes to CRPC development. Collectively, improvements in PC management require advances in biomarkers for PC diagnosis and recurrence risk assessment, as well as a deeper understanding of PC-associated genomic instability. In this thesis, three complementary projects are presented that collectively advance our knowledge in prognostic stratification and molecular risk factors for PC progression. First, we evaluated the Sig27 multigene panel, previously developed in our lab as a potential predictor of PC relapse (Biochemical Recurrence - BCR). We demonstrate that Sig27 possesses predictive power for BCR comparable to Oncotype DX and is strongly associated with immune-related pathways in PC. Sig27 metagene expression is enriched in tumor-associated macrophages (TAMs) and positively correlates with multiple immune checkpoints (ICs), including HAVCR2, TIGIT and CD96. Analyzing their 27 component genes, we identified five genes (TFEC, FPR3, NOD2, LAMP3, and MCTP1) that primarily contribute to Sig27&#x27;s association with immune-suppressive features of PC. Second, we further explored the role of a Sig27 gene component, LINC01089, in PC tumorigenesis, as a long non-coding RNA (lncRNA) previously implicated in other cancer types. Our findings reveal an oncogenic role for LINC01089: it enhances tumor cell proliferation and migration in vitro, promotes tumor growth in vivo, and confers resistance to androgen withdrawal in LNCaP and TRAMP-C2 cells. We further demonstrated that LINC01089 is upregulated in PC tumors and significantly predicts recurrence risk. In primary PCs, genes associated with LINC01089 are predominantly enriched in RNA splicing processes. Moreover, we constructed two novel multigene panels from the LINC01089 gene network, Overlap3 and Sig15, both of which captured RNA splicing features of PC and significantly predict recurrence. Given that RNA splicing is a common property of cancer, Sig15 also effectively stratifies poor prognosis across nine additional cancer types. Furthermore, we detected elevated circulating LINC01089 levels in plasma from 235 PC patients compared with 24 healthy individuals, benchmarking our data to PCA3, indicating a diagnostic potential of LINC01089 as a liquid-based biomarker. Third, we examined the possible association of FAM84B, previously characterized as a risk factor for PC in our lab, with the DNA damage response (DDR). Taking advantage of PC stable lines previously generated - FAM84B, FAM84B-ΔHRASLS (FAM84B mutant with a deletion of the HRASLS domain) and EV (empty vector) - we studied the impact of FAM84B on the DDR following etoposide-induced DNA damage. Our evidence indicates that FAM84B modulates DDR, as observed by reduced activation and/or recruitment of DDR factors including NSB1, ATM, H2AX, and CHEK2. Moreover, FAM84B conferred a survival advantage to tumor cells under DNA-damaging conditions. Altogether, these findings suggest that FAM84B mediated dysregulation of DDR may impair DNA repair, promote genome instability, and enhance tumorigenic potential. In conclusion, these studies integrate biomarker exploration with functional studies to uncover novel determinants of PC progression, providing insights with potential relevance for improving PC risk assessment and therapeutic strategies.","abstract_has_math":false,"creators":["Vega Neira, Sandra Jimena"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Tang, Damu"],"committee_chairs":[],"committee_members":[],"year":2026,"date_issued":"2026","date_published":"2026","updated_at":"2026-11-18T19:33:13Z","subjects":[],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/25581"],"render_values":[{"text":"https://doi.org/10.71548/25581","href":"https://doi.org/10.71548/25581","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/11375/33811","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/11375/33811","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F33811","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Tang, Damu"]},{"key":"dc:creator","label":"Author","values":["Vega Neira, Sandra Jimena"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2026-10-14T16:31:59Z"]},{"key":"dc:date.issued","label":"Date","values":["2026"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/11375/33811","https://doi.org/10.71548/25581"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["ABSTRACT Despite advances in understanding prostate cancer (PC) pathogenesis and the rapid development of new therapeutic approaches, PC remains the second leading cause of cancer death in men, highlighting the need to deepen our understanding of its etiology and improve patient management. Following curative-aimed therapies (surgery and chemotherapy), relapsed tumors (biochemical recurrence - BCR) develop with a significantly increased risk of metastasis. Given the fundamental role of androgen receptor (AR) in driving PC progression, metastatic PCs are standardly treated with androgen deprivation therapy (ADT). However, resistance frequently occurs in the form of castration-resistant PC (CRPC), representing the dominant cause of PC mortality. Metastatic PCs exhibit the highest level of chromosomal instability (CIN) among other metastatic cancers, and this genomic instability contributes to CRPC development. Collectively, improvements in PC management require advances in biomarkers for PC diagnosis and recurrence risk assessment, as well as a deeper understanding of PC-associated genomic instability. In this thesis, three complementary projects are presented that collectively advance our knowledge in prognostic stratification and molecular risk factors for PC progression. First, we evaluated the Sig27 multigene panel, previously developed in our lab as a potential predictor of PC relapse (Biochemical Recurrence - BCR). We demonstrate that Sig27 possesses predictive power for BCR comparable to Oncotype DX and is strongly associated with immune-related pathways in PC. Sig27 metagene expression is enriched in tumor-associated macrophages (TAMs) and positively correlates with multiple immune checkpoints (ICs), including HAVCR2, TIGIT and CD96. Analyzing their 27 component genes, we identified five genes (TFEC, FPR3, NOD2, LAMP3, and MCTP1) that primarily contribute to Sig27's association with immune-suppressive features of PC. Second, we further explored the role of a Sig27 gene component, LINC01089, in PC tumorigenesis, as a long non-coding RNA (lncRNA) previously implicated in other cancer types. Our findings reveal an oncogenic role for LINC01089: it enhances tumor cell proliferation and migration in vitro, promotes tumor growth in vivo, and confers resistance to androgen withdrawal in LNCaP and TRAMP-C2 cells. We further demonstrated that LINC01089 is upregulated in PC tumors and significantly predicts recurrence risk. In primary PCs, genes associated with LINC01089 are predominantly enriched in RNA splicing processes. Moreover, we constructed two novel multigene panels from the LINC01089 gene network, Overlap3 and Sig15, both of which captured RNA splicing features of PC and significantly predict recurrence. Given that RNA splicing is a common property of cancer, Sig15 also effectively stratifies poor prognosis across nine additional cancer types. Furthermore, we detected elevated circulating LINC01089 levels in plasma from 235 PC patients compared with 24 healthy individuals, benchmarking our data to PCA3, indicating a diagnostic potential of LINC01089 as a liquid-based biomarker. Third, we examined the possible association of FAM84B, previously characterized as a risk factor for PC in our lab, with the DNA damage response (DDR). Taking advantage of PC stable lines previously generated - FAM84B, FAM84B-ΔHRASLS (FAM84B mutant with a deletion of the HRASLS domain) and EV (empty vector) - we studied the impact of FAM84B on the DDR following etoposide-induced DNA damage. Our evidence indicates that FAM84B modulates DDR, as observed by reduced activation and/or recruitment of DDR factors including NSB1, ATM, H2AX, and CHEK2. Moreover, FAM84B conferred a survival advantage to tumor cells under DNA-damaging conditions. Altogether, these findings suggest that FAM84B mediated dysregulation of DDR may impair DNA repair, promote genome instability, and enhance tumorigenic potential. In conclusion, these studies integrate biomarker exploration with functional studies to uncover novel determinants of PC progression, providing insights with potential relevance for improving PC risk assessment and therapeutic strategies."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Doctor of Philosophy (Medical Science)"]},{"key":"dc:title","label":"Title","values":["Evaluation of Prostate Cancer-Associated Factors (SIG27, LINC01089, and FAM84B) and Their Contribution to Prostate Cancer Progression"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Tang, Damu"],"dc:creator":["Vega Neira, Sandra Jimena"],"dc:date.accessioned":["2026-10-14T16:31:59Z"],"dc:date.issued":["2026"],"dc:description.abstract":["ABSTRACT Despite advances in understanding prostate cancer (PC) pathogenesis and the rapid development of new therapeutic approaches, PC remains the second leading cause of cancer death in men, highlighting the need to deepen our understanding of its etiology and improve patient management. Following curative-aimed therapies (surgery and chemotherapy), relapsed tumors (biochemical recurrence - BCR) develop with a significantly increased risk of metastasis. Given the fundamental role of androgen receptor (AR) in driving PC progression, metastatic PCs are standardly treated with androgen deprivation therapy (ADT). However, resistance frequently occurs in the form of castration-resistant PC (CRPC), representing the dominant cause of PC mortality. Metastatic PCs exhibit the highest level of chromosomal instability (CIN) among other metastatic cancers, and this genomic instability contributes to CRPC development. Collectively, improvements in PC management require advances in biomarkers for PC diagnosis and recurrence risk assessment, as well as a deeper understanding of PC-associated genomic instability. In this thesis, three complementary projects are presented that collectively advance our knowledge in prognostic stratification and molecular risk factors for PC progression. First, we evaluated the Sig27 multigene panel, previously developed in our lab as a potential predictor of PC relapse (Biochemical Recurrence - BCR). We demonstrate that Sig27 possesses predictive power for BCR comparable to Oncotype DX and is strongly associated with immune-related pathways in PC. Sig27 metagene expression is enriched in tumor-associated macrophages (TAMs) and positively correlates with multiple immune checkpoints (ICs), including HAVCR2, TIGIT and CD96. Analyzing their 27 component genes, we identified five genes (TFEC, FPR3, NOD2, LAMP3, and MCTP1) that primarily contribute to Sig27's association with immune-suppressive features of PC. Second, we further explored the role of a Sig27 gene component, LINC01089, in PC tumorigenesis, as a long non-coding RNA (lncRNA) previously implicated in other cancer types. Our findings reveal an oncogenic role for LINC01089: it enhances tumor cell proliferation and migration in vitro, promotes tumor growth in vivo, and confers resistance to androgen withdrawal in LNCaP and TRAMP-C2 cells. We further demonstrated that LINC01089 is upregulated in PC tumors and significantly predicts recurrence risk. In primary PCs, genes associated with LINC01089 are predominantly enriched in RNA splicing processes. Moreover, we constructed two novel multigene panels from the LINC01089 gene network, Overlap3 and Sig15, both of which captured RNA splicing features of PC and significantly predict recurrence. Given that RNA splicing is a common property of cancer, Sig15 also effectively stratifies poor prognosis across nine additional cancer types. Furthermore, we detected elevated circulating LINC01089 levels in plasma from 235 PC patients compared with 24 healthy individuals, benchmarking our data to PCA3, indicating a diagnostic potential of LINC01089 as a liquid-based biomarker. Third, we examined the possible association of FAM84B, previously characterized as a risk factor for PC in our lab, with the DNA damage response (DDR). Taking advantage of PC stable lines previously generated - FAM84B, FAM84B-ΔHRASLS (FAM84B mutant with a deletion of the HRASLS domain) and EV (empty vector) - we studied the impact of FAM84B on the DDR following etoposide-induced DNA damage. Our evidence indicates that FAM84B modulates DDR, as observed by reduced activation and/or recruitment of DDR factors including NSB1, ATM, H2AX, and CHEK2. Moreover, FAM84B conferred a survival advantage to tumor cells under DNA-damaging conditions. Altogether, these findings suggest that FAM84B mediated dysregulation of DDR may impair DNA repair, promote genome instability, and enhance tumorigenic potential. In conclusion, these studies integrate biomarker exploration with functional studies to uncover novel determinants of PC progression, providing insights with potential relevance for improving PC risk assessment and therapeutic strategies."],"dc:description.degree":["Doctor of Philosophy (Medical Science)"],"dc:identifier.uri":["https://hdl.handle.net/11375/33811","https://doi.org/10.71548/25581"],"dc:language.iso":["en"],"dc:title":["Evaluation of Prostate Cancer-Associated Factors (SIG27, LINC01089, and FAM84B) and Their Contribution to Prostate Cancer Progression"],"dc:type":["Thesis"],"others:access_status":["open.access"]},"updated_at":"2026-11-18T19:33:13Z"}